Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks

RHYTHM PHARMACEUTICALS, INC.

BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.
Mean reduction >2.8 points in 'most' hunger score on 10-point scale in 600mg and 400mg cohorts.
Safety consistent with MC4R agonism; one discontinuation due to serious AE (rectal bleeding).
Rhythm plans End-of-Phase 2 meeting with FDA and EU scientific advice for registrational path.
Data from 26 of 27 patients continued into open-label extension as of July 7, 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.